Tags

Type your tag names separated by a space and hit enter

eluxadoline

General

Pronunciation:
el-ux-ad-oh-leen


Trade Name(s)

  • Viberzi

Ther. Class.
anti irritable bowel syndrome agents
mu-opioid receptor agonists

Controlled Substance Schedule: IV

Indications

Treatment of diarrhea – predominant irritable bowel syndrome (IBS-d).

Action

Acts as a agonist at mu-opioid receptors in the GI tract.

Therapeutic Effect(s):

↓ frequency and severity of abdominal pain/diarrhea associated with IBS-d.

Pharmacokinetics

Absorption: Some systemic absorption follows oral administration (bioavailaibility unknown).

Distribution: Unk.

Metabolism and Excretion: Mostly metabolized by the liver; <1% excreted in urine.

Half-life: 3.7–6 hr

TIME/ACTION PROFILE (effect on GI tract)

ROUTEONSETPEAKDURATION
POunknownunknown12 hr

Contraindication/Precautions

Contraindicated in:

  • Without a gallbladder (↑ risk of pancreatitis and/or sphincter of Oddi spasm);
  • Known/suspected biliary tract obstruction or sphincter of Oddi disease/dysfunction (↑ risk of sphincter of Oddi spasm)
  • Alcohol abuse/addiction or consumption of > 3 alcoholic beverages/day (↑ risk of pancreatitis);
  • History of pancreatitis/pancreatic disease/pancreatic duct obstruction (↑ risk of pancreatitis)
  • Severe hepatic impairment (Child-Pugh C);
  • Severe constipation/sequelae of constipation/known of suspected mechanical GI obstruction.

Use Cautiously in:

  • Mild-moderate hepatic impairment (dose reduction recommended)
  • Recreational opioid-experienced patients (may produce euphoria/psychological dependence)
  • Geri: ↑ risk of adverse reactions;
  • OB: Pregnancy (effects unknown)
  • Lactation: Consider maternal need for eluxadoline and potential risks of adverse effects on infant;
  • Pedi: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

CNS: dizziness, fatigue

GI: PANCREATITIS, constipation, abdominal distention, abdominal pain, flatulence, ↑liver enzymes, nausea, sphincter of Oddi spasm, vomiting

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

Route/Dosage

PO: (Adults) 100 mg twice daily; patients who lack a gallbladder, are unable to tolerate 100 mg twice daily or are taking concurrent OATP1P1 inhibitors– 75 mg twice daily.Hepatic Impairment
(Adults) Mild-moderate hepatic impairmentm– 75 mg twice daily.

Availability

Tablets: 75 mg, 100 mg

Assessment

  • Assess bowel function (quality and quantity of stools) periodically during therapy. Discontinue eluxadoline if constipation last more than 4 days.

Potential Diagnoses

Implementation

  • PO: Administer twice daily with food.

Patient/Family Teaching

  • Instruct patient to take eluxadoline as directed. If a dose is missed, omit and take next dose as scheduled; do not double doses.
  • Advise patient that eluxadoline is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed.
  • Advise patient to stop eluxadoline and notify health care professional if abdominal pain (acute epigastric or biliary [right upper quadrant] pain), may radiate to back or shoulder with or without nausea and vomiting) occur.
  • Caution patient to avoid more that 3 alcoholic drinks/day.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially other medications causing constipation.
  • Advise female patient to notify health care professional of pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Reduction of abdominal pain/diarrhea in patients with irritable bowel syndrome.

eluxadoline is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Davis’s Drug Guide App + Web powered by Unbound Medicine provides up-to-date information on 5000+ trade name and generic drugs. View on the web or download App to your iPhone, iPad, or Android smartphone or tablet. Davis Drug Guide PDF. Learn more.

Citation

Quiring, Courtney, et al. "Eluxadoline." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. www.drugguide.com/ddo/view/Davis-Drug-Guide/110358/6/eluxadoline.
Quiring C, Sanoski CA, Vallerand AH. Eluxadoline. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110358/6/eluxadoline. Accessed June 16, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Eluxadoline. In Davis's Drug Guide. Available from https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110358/6/eluxadoline
Quiring C, Sanoski CA, Vallerand AH. Eluxadoline [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 June 16]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110358/6/eluxadoline.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - eluxadoline ID - 110358 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110358/6/eluxadoline PB - F.A. Davis Company ET - 16 DB - Davis's Drug Guide DP - Unbound Medicine ER -